RCT | Assessing low-dose ketamine’s antidepressant & antisuicidal effects in patients with treatment-resistant depression

A Randomized Double-Blind Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation – International Journal of Neuropsychopharmacology

Commentary on Twitter

RCT: ketamine infusion (0.5 mg/kg) is a safe and effective treatment for patients with TRD and prominent suicidal ideation vs. midazolam. Response was noted when the current depressive episode lasted for <24 months and the number of failed AD is ≤4 https://t.co/QKNy8bUKBK pic.twitter.com/GyfQp0pmpO

— PfOL (@psychopharmacol) April 4, 2023